British pharmaceutical firm AstraZeneca has rejected a new takeover offer form US drugs giant Pfizer.
Does industry sponsorship of clinical trials bias the outcomes of the study? Does such sponsorship influence how doctors interpret the research findings? Does it affect healthcare professionals’ willingness to believe the results and integrate an experimental treatment into their practice?
Should countries allow companies to reverse engineer and sell generic drugs to keep their populations healthy at a lower cost?
Drug company GlaxoSmithKline has agreed to pay a $3 billion fine, the largest health care fraud fine in the history of the United States – the latest in a string of drug company penalties for improper promotion of drugs for “off-label,” or unapproved, uses.